Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats

Archives of Medical Science

Volumn 7, Issue 5, 2011, Pages 882-888

  Chou, Chu Lin ^a,b   Lai, Yu Hsien ^c   Lin, Teng Yi ^c   Lee, Tony J F ^a,d   Fang, Te Chao ^a,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aliskiren; Direct renin inhibitor; Fructose; Hypertension; Metabolic syndrome

Indexed keywords

ALISKIREN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; FLUID INTAKE; FOOD INTAKE; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE; HYPERTENSION; MALE; METABOLIC SYNDROME X; MICTURITION; NONHUMAN; RAT; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 81555210904     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.25566     Document Type: Article

References (36)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607. (Pubitemid 19004941)
2. Kostapanos MS, Liamis GL, Elisaf M. Features of the metabolic syndrome relating to cardiorenal outcomes. Arch Med Sci 2008; 4: 424-6.
3. Ferder L, Ferder MD, Inserra F. The role of high-fructose corn syrup in metabolic syndrome and hypertension. Curr Hypertens Rep 2010; 12: 105-12.
4. Ferrario CM. Importance of the renin-angiotensin-aldo - sterone system (RAS) in the physiology and pathology of hypertension. An overview. Drugs 1990; 39 Suppl 2: 1-8. (Pubitemid 20167008)
5. Fang TC, Huang WC. Angiotensin receptor blockade blunts hyperinsulinemia-induced hypertension in rats. Hypertension 1998; 32: 235-42.
6. Fang TC, Huang WC. Role of angiotensin II in hyper - insulinemia-induced hypertension in rats. J Hypertens 1998; 16: 1767-74.
7. Abuissa H, Jones PG, Marso SP, et al. Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-6. (Pubitemid 41224805)
8. Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-6. (Pubitemid 41242483)
9. Wood JM, Schnell CR, Cumin F, et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005; 23: 417-26. (Pubitemid 40279646)
10. Yarows SA, Oparil S, Patel S, et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008; 25: 1288-302.
11. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-46. (Pubitemid 351793017)
12. Huang BW, Chiang MT, Yao HT, et al. The effect of highfat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. Diabetes Obes Metab 2004; 6: 120-6.
13. Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Cardiac lipids and antioxidant status in high fructose rats and the effect of alpha-lipoic acid. Nutr Metab Cardiovasc Dis 2004; 14: 351-7. (Pubitemid 40459257)
14. Reungjui S, Roncal CA, Mu W, et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 2007; 18: 2724-31. (Pubitemid 47531199)
15. Shinozaki K, Ayajiki K, Nishio Y, et al. Evidence for a causal role of the renin-angiotensin system in vasculardysfunction associated with insulin resistance. Hypertension 2004; 43: 255-62. (Pubitemid 38174184)
16. Iyer SN, Katovich MJ, Raizada MK. Changes in angiotensin AT1 receptor density during hypertension in fructose-fed rats. Adv Exp Med Biol 1996; 396: 49-58. (Pubitemid 26164387)
17. Miatello R, Risler N, Gonzalez S, et al. Effects of enalapril on the vascular wall in an experimental model of syndrome X. Am J Hypertens 2002; 15: 872-8. (Pubitemid 35168426)
18. Miatello R, Risler N, Castro C, et al. Chronic administration of losartan reverses cardiovascular changes in hypertensive fructose-fed rats. Cell Mol Biol (Noisy-legrand) 2003; 49: 945-52.
19. Fogari R, Zoppi A, Mugellini A, et al. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Horm Metab Res 2010; 42: 892-6.
20. Kang YS, Lee MH, Song HK, et al. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 2011; 26: 1194-204.
21. Iwai M, Kanno H, Tomono Y, et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens 2010; 28: 1471-81.
22. Lastra G, Habibi J, Whaley-Connell AT, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-8.
23. Dong YF, Liu L, Kataoka K, et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010; 53: 180-91.
24. Igarashi M, Hirata A, Nozaki H, et al. Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats. Diabetes Res Clin Pract 2007; 75: 267-77. (Pubitemid 46074213)
25. Iyer SN, Katovich MJ. Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens 1996; 9: 662-8. (Pubitemid 26266604)
26. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-302. (Pubitemid 34535341)
27. Rao RH. Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 1994; 7: 655-60. (Pubitemid 24265163)
28. Folli F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-9. (Pubitemid 29179280)
29. Habibi J, Whaley-Connell A, Hayden MR, et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008; 149: 5643-53.
30. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-33. (Pubitemid 28088387)
31. Iimura O, Shimamoto K, Matsuda K, et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8: 353-7.
32. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807-25. (Pubitemid 36379323)
33. Ezra-Nimni O, Ezra D, Peleg E, et al. Trandolapril and endothelin antagonist LU-135252 in the treatment of the fructose-induced hypertensive, hyperinsulinemic, hyper - triglyceridemic rat. Am J Hypertens 2003; 16: 324-8. (Pubitemid 36384762)
34. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-82. (Pubitemid 39336681)
35. Stucchi P, Cano V, Ruiz-Gayo M, et al. Aliskiren reduces body-weight gain, adiposity and plasma leptin during dietinduced obesity. Br J Pharmacol 2009; 158: 771-8.
36. Rosselli MS, Burgueno AL, Carabelli J, et al. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis 2009; 206: 119-26.